Literature DB >> 21560059

Basic science in Parkinson's disease: its impact on clinical practice.

Jörg B Schulz1, Manfred Gerlach, Gabriele Gille, Wilfried Kuhn, Martina Müngersdorf, Peter Riederer, Martin Südmeyer, Albert Ludolph.   

Abstract

Failures in clinical studies that were aimed to prove disease-modifying effects of treatments in Parkinson's disease (PD) raise the question as to whether basic sciences have had an impact in clinical practice. This question implies that despite well-publicized results obtained by intensive genetic and pathogenetic research, e.g. the identification of mutations and cellular biochemical pathways that underlie Parkinson-specific neurodegeneration, no relevant disease-modifying treatment options have been developed. This view neglects the fact that today there are plenty of dopaminergic and non-dopaminergic and surgical treatment options, and that PD was not treatable 50 years ago. This progress was made possible only by basic science. In this review, we underline the success of previous basic science for daily practice in PD and its impact for the understanding and development of an early diagnosis. Early, even pre-symptomatic diagnosis might be key to successfully establish disease-modifying treatments.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21560059     DOI: 10.1007/s00415-011-6040-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  66 in total

1.  3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists.

Authors:  A CARLSSON; M LINDQVIST; T MAGNUSSON
Journal:  Nature       Date:  1957-11-30       Impact factor: 49.962

2.  The oxidation of adrenaline and other amines.

Authors:  H Blaschko; D Richter; H Schlossmann
Journal:  Biochem J       Date:  1937-12       Impact factor: 3.857

3.  Estimated life expectancy of Parkinson's patients compared with the UK population.

Authors:  Lianna S Ishihara; Anne Cheesbrough; Carol Brayne; Anette Schrag
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-30       Impact factor: 10.154

4.  Amantadine in the treatment of Parkinson's disease.

Authors:  R S Schwab; A C England; D C Poskanzer; R R Young
Journal:  JAMA       Date:  1969-05-19       Impact factor: 56.272

5.  Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants.

Authors:  A Björklund; U Stenevi
Journal:  Brain Res       Date:  1979-11-30       Impact factor: 3.252

6.  Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease.

Authors:  A L Benabid; P Pollak; A Louveau; S Henry; J de Rougemont
Journal:  Appl Neurophysiol       Date:  1987

7.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

8.  Stromal cell-derived inducing activity, Nurr1, and signaling molecules synergistically induce dopaminergic neurons from mouse embryonic stem cells.

Authors:  Dong-Wook Kim; Sangmi Chung; Mikyeong Hwang; Andrew Ferree; Hsing-Chen Tsai; Jae-Joon Park; Seungsoo Chung; Taick Sang Nam; Un Jung Kang; Ole Isacson; Kwang-Soo Kim
Journal:  Stem Cells       Date:  2005-08-25       Impact factor: 6.277

Review 9.  MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease.

Authors:  M Gerlach; P Riederer; H Przuntek; M B Youdim
Journal:  Eur J Pharmacol       Date:  1991-12-12       Impact factor: 4.432

10.  Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis.

Authors:  C Warren Olanow; Jean-Michel Gracies; Christopher G Goetz; A Jon Stoessl; Thomas Freeman; Jeffrey H Kordower; James Godbold; Jose A Obeso
Journal:  Mov Disord       Date:  2009-02-15       Impact factor: 10.338

View more
  1 in total

1.  Inhibition of the Nrf2/HO-1 Axis Suppresses the Mitochondria-Related Protection Promoted by Gastrodin in Human Neuroblastoma Cells Exposed to Paraquat.

Authors:  Marcos Roberto de Oliveira; Flávia de Bittencourt Brasil; Cristina Ribas Fürstenau
Journal:  Mol Neurobiol       Date:  2018-07-11       Impact factor: 5.590

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.